As a driver mutation, the KRAS mutant is conceptually attractive since it is tumor-specific and biologically important to tumor progression and is likely to be expressed in all kinds of tumors (68), which makes the KRAS mutant a hot spot for adoptive cell therapy. This evidence concerns the gene KRAS and neoplasm.